Eos exists to support founders.
Innovation in science, engineering and technology is key to improving quality of life, making agriculture and aquaculture more sustainable, mitigating climate change, finding new energy solutions and much more.
Commercial returns as well as positive impact are the key metrics for all of our work. By addressing key issues facing society, you are by definition addressing markets of scale.
Deep roots in Scotland, with a global perspective.
Insert a quote here from one of the team members that relates to this section maybe, or metric values perhaps?
Team member, Title
Connections with world-class research universities at home and across the UK remains crucial for our work, as well as networks into industry. Finding, understanding, and scaling innovation is not something that can be done at arm’s length and because all of our investments have global application, we spend an equal amount of time supporting them to scale into larger commercial markets.
Most funders are not willing to back nascent ventures until they have a financial track record, because they don’t understand the potential and IP underlying knowledge intensive companies. Eos does. We firmly believe that commercial returns should be commensurate with early-stage risk, and to realise these returns you need sector specialism and the capacity to work closely with portfolio companies.
Trust, hard work and discretion are important values at Eos. Everyone who is a part of the Eos eco-system has a level of altruistic motivation, a fascination in the impact these businesses can have within industry and within society. Commercial returns are clearly also important and so knowing that Eos has the depth of knowledge, network, and work ethic to support companies is of paramount importance.
We welcome new founders and new investors who share the belief that scientific, engineering and technology innovations are the best way to balance commercial success whilst also having positive impact on major global issues.
The Eos team is made up of founders, scientists, record breakers, industry leaders, and government advisors.
Andrew McNeill
Managing Partner
Mark Beaumont
Partner, Investor Relationships
Andrew Durkie
Partner
Calum Keddie
Investment Executive
Jill Arnold
Investment Relationship Director
Ana Stewart
Partner
Chris Brinsmead
Partner
Rick Clark
Partner
Anne Muir
Director of Portfolio
Rob Halliday
Investment Director
Andy Lothian
Growth Advisor
Sandy Kennedy
Growth Advisor
Eos invests through an Angel Syndicate, an EIS Innovation Fund & Venture Partnerships.
We also have Scottish Enterprise co-investment status. The breadth of this co-investment is important for scaling, balancing of risk and also to build relationships with people and organisations who can understand and help our businesses grow over the long term.
A growing & thriving portfolio
Ishani Malhotra
Carcinotech is a MedTech company manufacturing 3D printed mini tumours developed from patient-specific cancer stem cells, primary cells and established cell lines.
Eos first invested: April, 2022
Giovanna Laudisio
Biodegradable, sustainable and cost competitive cellulose microparticles to replace plastic microbeads
Eos first invested: June, 2022
Richard Hammond
Penrhos Bio offers Remora technology, inspired by nature, that protects against bacteria, fungi, and algae, to provide self-cleaning surfaces.
Eos first invested: September, 2022
David McElroy Phd
Pioneering the discovery, development and sustainable production of high-value plant natural products
Eos first invested: December, 2022
Laverock Therapeutics is developing a unique gene silencing platform for the creation of programmable advanced therapies.
Eos first invested: June, 2023
Lee Cronin
Chemify is building the digital chemistry infrastructure to enable worldwide access to any desired compound instantly and on-demand
Eos first invested: August, 2023
Clare Waring
Europes first cancer drug accelerator. Finding assets, creating spin-outs, commercialising cancer therapies.
Eos first invested: June, 2020
Rotimi Alabi
Lab-on-a-chip’ technology that delivers oil analysis 1000x faster and 10x cheaper than the current ‘send the sample to laboratory approach.
Eos first invested: December, 2020
Richard Kuo
Specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers.
Eos first invested: July, 2021
Gavin Munro
Formed in 2014 to offer Adjusta-Cone® as the world’s first fully adjustable differential pressure cone meter for natural gas.
Eos first invested: January, 2020
Joel Watt
Connects seafood buyers and suppliers, giving them the right tools to trade efficiently, negotiate prices and process deliveries across Europe – all in real-time, 24/7.
Eos first invested: October, 2019
Dr Mark Hegarty
Offers a revolutionary spectroscopic liquid biopsy with artificial intelligence for the early detection of cancer and other diseases.
Eos first invested: February, 2019
Dr Dave Hughes
An award winning Scottish sensors company utilising thin-film processes to eliminate conventional limitations in ultrasound sensors.
Eos first invested: April, 2018
Jim Laird
ABUNDA mycoprotein is a fermented food ingredient, rich in protein and fibre. Naturally fortified in B12, zinc and iron. ABUNDA is highly nutritious.
Eos first invested: June, 2017
Prof. Ian A. Johnston
A provider of specialist genetics and breeding management services to the aquaculture industry.
Eos first invested: March, 2016
Prof. W. H. Stimson
An early stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for Virology, Cancer, Atopic Dermatitis and Psoriasis.
Eos first invested: July, 2015
